Diaceutics Plc · LSE:DXRX
Diaceutics — Investor Presentation (May 2025)
17 slides from Diaceutics's investor presentation, May 2025
Slide 1: Helping pharma find patients
Helping pharma find patients Corporate Overview – May 2025 Ryan Keeling | Chief Executive Officer | [email protected] Nick Roberts | Chief Financial Officer | [email protected] © cop yrig ht Diaceutics 2024 2025 1 Per mission must be so ught from Diace utics if yo u wish to rep r
Slide 2: Disclaimer and Forward-Looking Statements
Disclaimer and Forward-Looking Statements Disclaimer : The information provided in this presentation is for the sole use of those attending the presentation This presentation has been prepared by Diaceutics the (“Company”). “Presentation” means this document, any oral presentation, any question and
Slide 3: 2024 Highlights
2024 Highlights • Continued progress across our key value drivers • Completed our two-year investment cycle - on time and to budget • Enhanced platform scale and capabilities - including deployment of cutting-edge AI • Expansion of our team and investing in talent • DXRX Signal identified more than
Slide 4: Operational dashboard – FY 2024
Operational dashboard – FY 2024 7 enterprise-wide 199 people inc. 85 customer 52 active engagements new VP therapeutic customers ARR of £10.6m hires/promotions brands Up from 4 and 184 at Dec-23 Up 23% from Up 18% from 44 £7.0m in 2023 69 in 2023 in 2023 Leveraging propriety AI to increase data ROI
Slide 5: Financial strength
Financial strength Ability to deliver exceptionally high margins through operational leverage Revenue CAGR of 32% over past 3 years Growing ARR revenues and future revenue visibility Seven enterprise-wide engagements with blue-chip customers driving momentum Strong balance sheet – no debt and cash o
Slide 6: Financial dashboard – FY 2024
Financial dashboard – FY 2024 Revenue Annual Recurring Revenue Order book value Gross profit margin Cash & equivalents £32.2m £16.8m £24.9m 88% £12.7m Up 36% NRR of 109% £17.7m to be Strong In line with CAGR of 32% recognised within operational investment plans over 3 yrs 12 months leverage from £23
Slide 7: We help pharma find patients - unique assets
We help pharma find patients - 3 unique assets 1. Lab network 2. Data 3. DXRX Platform Global network of World’s largest World’s first diagnostic labs repository of commercialisation platform for healthcare data precision medicine Pharma Labs Physicians Patients • ID patients daily • ↑ Diagnostic •
Slide 8: What we do - A DXRX Signal case study
What we do - A DXRX Signal case study The result: The situation: increase in patients Client ROI: A pharma client needed to locate Upon switching on DXRX Signal in Each patient worth an average revenue of patients with a specific lung cancer week 27 of year 1 the N of patients $220k for client. With
Slide 9: What is Precision Medicine?
What is Precision Medicine? Precision Medicine (PM) is the tailoring of medical treatment to the individual characteristics of each patient – a patient’s unique genetic profile makes them susceptible to certain diseases and can influence which treatments will be safe and effective for them PM is fas
Slide 10: The Precision Medicine Challenge
The Precision Medicine Challenge PM drugs are With new PM drugs typically PM drugs are highly inherently actionable have a smaller efficacious, but it dependent on their biomarkers entering patient population, can be challenging diagnostic pathway the market making patients to provide constantly it’
Slide 11: Powered by our DXRX Platform - PMx Supercharges our Commercialisation Solution
Powered by our DXRX Platform - PMx Supercharges our Commercialisation Solution for Biopharma Launched in 2022, Signal Launched in 2024, PMx enables Biopharma sales supercharges the impact of signal team to find patients & – enabling us to engage with engage physicians physicians directly Direct to p
Slide 12: PMx Enables us to Unlock Greater Value for Biopharma
PMx Enables us to Unlock Greater Value for Biopharma and Take a Larger Share of this Value •PMx V can potentially increase annual revenue per therapeutic brand from £0.4m to £3m+ Expanding our share of the Evolving our relationships from commercialisation budget vendor to partner Average revenue per
Slide 13: PMx Integrates our Full Commercialisation Toolkit
PMx Integrates our Full Commercialisation Toolkit Understand Strategy Strategy Tracking Adoption the market development implementation Understand uptake Drive precision Data products Professional Scientific & medicine therapy and conversion to & professional services - to build a Engagement prescrip
Slide 14: Moving the Needle for our Customers
Moving the Needle for our Customers Delivering customer-centric excellence is critical to our strategy. This year we have achieved a 3.7/4 satisfaction score, with customers providing the following snippets of feedback: “One of our most important business “Diaceutics is front of mind for future “Cle
Slide 15: Industry Leaders in Diagnostic Commercialisation
Industry Leaders in Diagnostic Commercialisation RYAN KEELING SARAH BONDI MARIANNA SCIORTINO Chief Executive Officer & VP Data Partnerships & Strategy VP Sales Co-Founder NICK ROBERTS KEVIN ENTWISTLE MADELINE BROWN Chief Financial Officer VP Advisory Services VP Chief of Staff JORDAN CLARK KELLY WIL
Slide 16: Helping Pharma Find Patients
Helping Pharma Significant & Growing Market Opportunity Find Patients Global pharma rapidly shifting to precision medicine to find more patients, capture lost revenue and increase profitability Growth Driven by Customer Success Strong Competitive Compelling Financial Demonstrable Advantage Value Pro
Slide 17: Team & Contacts
Team & Contacts Ryan Keeling Nick Roberts Chief Executive Officer Chief Financial Officer [email protected] Hayley Palmer | Canaccord Genuity | [email protected] Julie Simmonds | Panmure Liberum | [email protected] Natalia Webster | RBC Capital Markets | natalia.webster@